Our World

Brazil

Egypt

Europe

Hong Kong

Malaysia

Mexico

Morocco

Philippines

Saudi Arabia

South Africa

Taiwan

Thailand

Tunisia

Turkey

UAE

USA

Vietnam

Canada

Global HQ
Contact Us
Biocon Biocologics Logo
  • About Us
    • Overview
    • Our Business
    • Board of Directors
    • Executive Committee
    • Scientific Publications
    • Awards & Recognition
    • Investor Information
    • Our Legacy
  • Products
    • Overview
    • Product Locator
  • Business
    • Overview
    • Global Biosimilars Portfolio
    • Global Footprint
    • Partners
    • Emerging Markets
    • Biocon Biologics U.S.
    • Biocon Biologics EU
    • Biocon Biologics in Canada
  • Capabilities
    • Research & Development
    • Quality & Compliance
    • Global Scale Manufacturing
      • India
      • Malaysia
  • Commitment
    • Overview
    • EHS Certifications
  • News
    • Overview
    • Company Statements
    • Stories
    • Media Stories
    • Media Contacts
    • Video Gallery
    • Resource Center
  • Careers
    • Working With Us
    • Now Hiring
  • Stories
    • Overview
    • Brand Stories
    • Patients’ Stories
    • Employee Stories
Site Logo

Biocon Foundation conducts awareness session in 14 Government Schools

  • Thu, 06-Jun-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market

  • Tue, 21-May-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr

  • Thu, 16-May-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India

  • Thu, 14-Mar-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®

  • Mon, 04-Mar-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®

  • Thu, 29-Feb-2024
  • Posted by: Biocon Biologics
No Comments

Company Statement on rh-Insulin for Veterinary use

  • Thu, 29-Feb-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Included in S&P Global Sustainability Yearbook 2024

  • Tue, 20-Feb-2024
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

  • Fri, 09-Feb-2024
  • Posted by: Biocon Biologics
No Comments

Company Statement on bBevacizumab

  • Fri, 09-Feb-2024
  • Posted by: Biocon Biologics
No Comments
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 31

Quick Links

  • About Us
  • News
  • Our Stories
  • Investor Information
  • Biocon Limited
  • Syngene
  • Biocon Foundation
  • Biocon Academy

Business

  • U.S.
  • Europe

RECOMMENDED SITES

  • Science Gallery
  • ABLE
  • Immuneel Therapeutics
  • Bicara Therapeutics
  • Equillium
  • Biocon Blog

Get in Touch

  • Contact Us
  • Sitemap
Report adverse events/side effects/product complaints and/or to submit medical inquiries for Biocon Biologics Limited & BBL Affiliate products.

* Cookie Policy | Privacy Policy | Terms of Use © 2026, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Our Spring Sale Has Started

You can see how this popup was set up in our step-by-step guide: https://wppopupmaker.com/guides/auto-opening-announcement-popups/